Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Analysts at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for Amicus Therapeutics in a report issued on Tuesday, April 1st. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.06 per share for the quarter, up from their previous estimate of $0.04. The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics' Q2 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.13 EPS, FY2026 earnings at $0.36 EPS, Q1 2027 earnings at $0.10 EPS and FY2027 earnings at $0.56 EPS.
Several other analysts have also recently commented on FOLD. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Wells Fargo & Company dropped their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, Morgan Stanley restated an "equal weight" rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Amicus Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.75.
Check Out Our Latest Stock Report on Amicus Therapeutics
Amicus Therapeutics Stock Down 6.3 %
NASDAQ:FOLD traded down $0.50 on Wednesday, hitting $7.50. 3,184,754 shares of the company's stock traded hands, compared to its average volume of 2,537,963. The company has a market cap of $2.30 billion, a PE ratio of -41.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. Amicus Therapeutics has a 1 year low of $7.39 and a 1 year high of $12.65. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The firm has a 50-day moving average price of $9.16 and a 200-day moving average price of $9.88.
Institutional Trading of Amicus Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. HealthInvest Partners AB raised its stake in shares of Amicus Therapeutics by 18.6% in the 4th quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company's stock valued at $3,076,000 after acquiring an additional 51,368 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Amicus Therapeutics by 13.5% in the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock valued at $255,936,000 after purchasing an additional 2,856,101 shares during the period. Tempus Wealth Planning LLC acquired a new stake in shares of Amicus Therapeutics in the fourth quarter worth $259,000. Neo Ivy Capital Management bought a new stake in shares of Amicus Therapeutics during the 3rd quarter worth $702,000. Finally, Intech Investment Management LLC boosted its holdings in shares of Amicus Therapeutics by 59.7% during the 4th quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company's stock worth $1,175,000 after buying an additional 46,633 shares during the period.
Amicus Therapeutics Company Profile
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Read More
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
